Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer

BACKGROUND: Currently, programmed death ligand-1 (PD-L1) expression has been widely applied in clinical trials and real-world clinical practice as a major biomarker for the efficacy of immune-checkpoint inhibitors. The purpose of this study is to reveal the distribution and concordance of PD-L1 expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Fangqiu, Deng, Chaoqiang, Sun, Wenrui, Zheng, Qiang, Jin, Yan, Li, Yuan, Zhang, Yang, Chen, Haiquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636784/
https://www.ncbi.nlm.nih.gov/pubmed/36335353
http://dx.doi.org/10.1186/s12931-022-02201-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636784/
https://www.ncbi.nlm.nih.gov/pubmed/36335353
http://dx.doi.org/10.1186/s12931-022-02201-8

Ejemplares similares